DarioHealth (NASDAQ:DRIO) Now Covered by Analysts at Alliance Global Partners

Key Points

• Alliance Global Partners initiated coverage of DarioHealth with a Buy rating and a $12 price target, implying 67.13% upside from the prior close.
• Analyst opinions remain mixed: two rate the stock Buy, one Hold and one Sell, producing a consensus Hold rating and $10 average target price.
• DarioHealth reported a quarterly loss of $0.85 per share, better than the expected $1.22 loss, but revenue of $5.18 million missed estimates and the company continued to post negative profitability metrics.

Analysts at Alliance Global Partners assumed coverage on shares of DarioHealth (NASDAQ:DRIO - Get Free Report) in a research report issued on Wednesday. The firm set a "buy" rating and a $12.00 price target on the stock. Alliance Global Partners' price target would suggest a potential upside of 67.13% from the stock's previous close.

A number of other research analysts have also recently issued reports on the stock. Stifel Nicolaus reiterated a "buy" rating and issued a $10.00 target price on shares of DarioHealth in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DarioHealth in a report on Friday, July 10th. Finally, TD Cowen reduced their price objective on DarioHealth from $11.00 to $8.00 and set a "hold" rating on the stock in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $10.00.

DarioHealth Stock Down 2.4%

Shares of NASDAQ:DRIO opened at $7.18 on Wednesday. DarioHealth has a 52 week low of $5.84 and a 52 week high of $17.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. The company's fifty day moving average is $7.09 and its 200-day moving average is $8.16. The company has a market capitalization of $52.72 million, a PE ratio of -1.17 and a beta of 1.11.

DarioHealth (NASDAQ:DRIO - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.22) by $0.37. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. The business had revenue of $5.18 million during the quarter, compared to analysts' expectations of $5.92 million. Equities research analysts predict that DarioHealth will post -3.12 earnings per share for the current fiscal year.

Insider Activity at DarioHealth

In other news, Director Dennis Matheis bought 14,430 shares of the company's stock in a transaction dated Thursday, July 23rd. The stock was bought at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the director directly owned 43,026 shares in the company, valued at $298,170.18. The trade was a 50.46% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 3.50% of the company's stock.

Institutional Trading of DarioHealth

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new position in DarioHealth during the 4th quarter valued at about $35,000. BlackRock Inc. acquired a new stake in shares of DarioHealth during the 2nd quarter worth approximately $249,000. Geode Capital Management LLC grew its position in shares of DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company's stock worth $564,000 after buying an additional 31,063 shares during the period. XTX Topco Ltd raised its stake in shares of DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company's stock worth $42,000 after buying an additional 43,513 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in DarioHealth in the second quarter valued at approximately $4,030,561,000. 33.39% of the stock is currently owned by institutional investors and hedge funds.

About DarioHealth

DarioHealth NASDAQ: DRIO is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source